NCT07658261Completed
Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization. Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 14 Jun 2026
- Start date
- 1 May 2024
- Primary completion date
- 1 May 2024
- Lead sponsor
- Arya Habibi
- Diseases
- Obesity
- NCT number
- NCT07658261
What you commit to
- Study type: Interventional
- Participants enrolled: 36
- From 1 May 2024 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anti-obesity medications.
- Use of anabolic steroids, sports supplements, or fat-burning supplements.
Other illness
- Presence of metabolic diseases, including diabetes mellitus.
- Presence of cardiovascular or respiratory diseases.
Other
- Musculoskeletal or joint injuries that could interfere with exercise participation.
- Regular alcohol consumption or tobacco use.
- Absence from more than two training sessions during the intervention period.
- Withdrawal of consent or unwillingness to continue participation.
Who the study is looking for
- Male participants aged 20 to 45 years.
- Body mass index (BMI) ≥25 kg/m².
- Overweight or obese status.
- No participation in regular resistance or aerobic exercise during the previous 6 months.
- Willingness to participate and provide written informed consent.
Age in the registry: 20 years to 45 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Sports and Health Sciences of the University of Tehran Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.